Breaking News Instant updates and real-time market news.

ITEK

Inotek Pharmaceuticals

$2.62

-0.41 (-13.53%)

, FLXN

Flexion

$29.93

2.81 (10.36%)

17:30
10/06/17
10/06
17:30
10/06/17
17:30

On The Fly: After Hours Movers

HIGHER: Inotek Pharmaceuticals (ITEK), up 3.8% after Opaleye Management reported a 5.76% passive stake in the company... Flexion (FLXN), up 2.7% after it said that Zilretta received FDA approval. LOWER: Limoneira (LMNR), down 6.8% after CEO Harold Edwards disclosed the sale of 6,652 common shares of the company... Medtronic (MDT), down 1.9% after it said it estimates an impact to both revenue and adjusted earnings up to $250M in the fiscal 2018 second quarter due to Hurricane Maria.

ITEK

Inotek Pharmaceuticals

$2.62

-0.41 (-13.53%)

FLXN

Flexion

$29.93

2.81 (10.36%)

LMNR

Limoneira

$22.53

-0.51 (-2.21%)

MDT

Medtronic

$79.81

0.3 (0.38%)

  • 06

    Oct

  • 09

    Oct

ITEK Inotek Pharmaceuticals
$2.62

-0.41 (-13.53%)

07/12/17
ADAM
07/12/17
DOWNGRADE
ADAM
Hold
Inotek Pharmaceuticals downgraded to Hold from Buy at Canaccord
Canaccord analyst Dewey Steadman downgraded Inotek Pharmaceuticals to Hold with a $1 price target following disappointing top-line data for its Phase 2 fixed-dose combination trial which did not demonstrate any benefit in any of the arms tested.
01/03/17
PIPR
01/03/17
DOWNGRADE
PIPR
Neutral
Inotek Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer downgraded Inotek Pharmaceuticals to Neutral saying that while timolol appeared active in the Phase III MATrX-1 study, only the highest dose of tranodenoson came close but still missed the primary endpoint. The analyst wants to see "clearer path towards clinical, regulatory and commercial success" before recommending the shares. He cut his price target for the shares to $3 from $24. Inotek is down 63%, or $3.85, to $2.25 in pre-market trading.
01/04/17
ROTH
01/04/17
NO CHANGE
Target $3
ROTH
Buy
Inotek Pharmaceuticals price target lowered to $3 from $10 at Roth Capital
Roth Capital analyst Sa'ar Yaniv lowered his price target for Inotek Pharmaceuticals to $3 from $10 after its MATrX-1 failed to demonstrate statistically significant decrease in intraocular pressure in glaucoma patients compared with placebo. Despite the "disappointing setback," the analyst believes that value remains in the trabodenoson franchise. He reiterates a Buy rating on the shares.
07/11/17
HCWC
07/11/17
DOWNGRADE
HCWC
Neutral
Inotek Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis downgraded Inotek Pharmaceuticals to Neutral after the company decided not to take trabodenoson forward into Phase 3 testing in glaucoma. The most likely outcome of the company's strategic review is a reverse merger with a private company to put its $109M in cash to work with new assets, Davis tells investors in a research note. He cut his price target for the shares to $2 from $7.
FLXN Flexion
$29.93

2.81 (10.36%)

09/29/17
WELS
09/29/17
NO CHANGE
WELS
Flexion's Zilretta likely to be approved by FDA, says Wells Fargo
Wells Fargo analyst David Maris talked to Flexion's management ahead of the October 6 PDUFA for Zilretta, and Maris continues to believe the FDA will approve the drug, which has "the potential to be a game changer in osteoarthritis knee pain treatment." Maris maintained an Outperform rating and $32 price target on Flexion shares.
10/06/17
WELS
10/06/17
NO CHANGE
WELS
Flexion price target raised to $39 from $32 at Wells Fargo
Wells Fargo analyst David Maris maintained his Outperform rating on Flexion and raised his price target to $39 from $32 after the FDA approved the company's Zilretta for the treatment of osteoarthritic knee pain, which Maris believes will be "the new standard of care for this condition."
08/24/17
NORL
08/24/17
INITIATION
Target $40
NORL
Outperform
Flexion initiated with an Outperform at Northland
Northland initiated Flexion with an Outperform and a $40 price target saying lead candidate, Zilretta, is positioned to emerge as the first sustained release, non-opioid, intra-articular injectablefor treating osteoarthritis knee (pain. Zilretta has major advantages to existing intra-articular corticosteroids injections as it has a rapid onset of action, provides durable pain relief for at least 3 months, and avoids elevating bloodglucose levels, the firm's analyst wrote in a note to investors.
08/24/17
08/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Zimmer Biomet (ZBH) initiated with a Buy at Gabelli. 2. Foamix (FOMX) initiated with a Buy at H.C. Wainwright. 3. Netlist (NLST) initiated with a Buy at Roth Capital. 4. Flexion (FLXN) initiated with an Outperform at Northland. 5. USA Technologies (USAT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
LMNR Limoneira
$22.53

-0.51 (-2.21%)

MDT Medtronic
$79.81

0.3 (0.38%)

09/15/17
LEHM
09/15/17
INITIATION
Target $76
LEHM
Equal Weight
Dexcom initiated with an Equal Weight at Barclays
Barclays analyst Matthew Taylor started Dexcom (DXCM) with an Equal Weight rating and $76 price target. The analyst sees a "choppy" few quarters for the business and shares amid competition from Abbott (ABT) and Medtronic (MDT).
10/03/17
SBSH
10/03/17
NO CHANGE
SBSH
Citi's general surgery survey 'very positive' for Intuitive Surgical
Citi analyst Amit Hazan says his firm's general surgery survey is "very positive" for Intuitive Surgical (ISRG), and "much less so" for Medtronic (MDT) and Johnson & Johnson (JNJ). Robotic procedures are expected to be up about 30% this year and next, with ventral hernia leading, Hazan tells investors in a research note partially titled "It's a Good Time to be a Robot." He believes robotic is really starting to hurt laparoscopy and that Medtronic and J&J will likely be forced to talk about the headwind publicly.
10/05/17
PIPR
10/05/17
NO CHANGE
PIPR
J&J exit from insulin pumps a 'clear win' for Medtronic, says Piper Jaffray
After Animas, one of Johnson & Johnson's (JNJ) companies, announced that it intends to discontinue the manufacturing and sale of insulin pumps and selected Medtronic (MDT) as its transition partner, Piper Jaffray analyst Matt O'Brien called the news a "clear win" for Medtronic. For DexCom (DXCM), which has partnered with Animas, this decision is likely a modest negative, while Insulet (PODD) and Tandem (TNDM) may be able to capture some share from Animas pump patients who look for other therapeutic options, added O'Brien.
10/05/17
COWN
10/05/17
NO CHANGE
COWN
J&J exit 'great opportunity' for Insulet and Tandem, says Cowen
Cowen analyst Doug Schenkel says close to 10% of the U.S. insulin pump market is up for grabs over the next two years after Johnson & Johnson's (JNJ) Animas announced it is exiting the pump business. Medtronic (MDT) is likely to get the majority of patients initially, but the news is a "great opportunity" for Insulet (PODD) and Tandem Diabetes Care (TNDM), Schenkel tells investors in a research note. The analyst sees risk for Dexcom (DXCM), but believes the vast majority of its users will remain, regardless of pump choice.

TODAY'S FREE FLY STORIES

19:15
10/20/17
10/20
19:15
10/20/17
19:15
General news
Breaking General news story  »

Federal Reserve Chair…

ATRS

Antares Pharma

$2.18

0.06 (2.83%)

18:59
10/20/17
10/20
18:59
10/20/17
18:59
Hot Stocks
FDA cannot approve Antares Pharma's Xyosted NDA »

Antares Pharma announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

18:55
10/20/17
10/20
18:55
10/20/17
18:55
Conference/Events
Federal Reserve Chairperson delivers a lecture at NEC Dinner »

Federal Reserve…

SHIP

Seanergy Marine

$1.24

0.0199 (1.63%)

17:50
10/20/17
10/20
17:50
10/20/17
17:50
Syndicate
Breaking Syndicate news story on Seanergy Marine »

Seanergy Marine files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HLI

Houlihan Lokey

$41.56

0.18 (0.43%)

17:49
10/20/17
10/20
17:49
10/20/17
17:49
Syndicate
Breaking Syndicate news story on Houlihan Lokey »

Houlihan Lokey files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

GEO

Geo Group

$26.20

0.2 (0.77%)

17:48
10/20/17
10/20
17:48
10/20/17
17:48
Syndicate
Breaking Syndicate news story on Geo Group »

Geo Group files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

, AIMT

Aimmune

$25.66

-0.06 (-0.23%)

17:37
10/20/17
10/20
17:37
10/20/17
17:37
Hot Stocks
DBV sinks following peanut allergy trial miss, Aimmune soars »

Shares of DBV…

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

AIMT

Aimmune

$25.66

-0.06 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

KALV

KalVista

$11.26

1.99 (21.47%)

, DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:24
10/20/17
10/20
17:24
10/20/17
17:24
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: KalVista (KALV),…

KALV

KalVista

$11.26

1.99 (21.47%)

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IPCI

Intellipharmaceutics

17:23
10/20/17
10/20
17:23
10/20/17
17:23
Hot Stocks
Breaking Hot Stocks news story on Intellipharmaceutics »

Armistice Capital reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DBVT

DBV Technologies

$48.07

0.92 (1.95%)

17:21
10/20/17
10/20
17:21
10/20/17
17:21
Hot Stocks
DBV Technologies: PEPITES trial does not reach primary endpoint »

DBV Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFC

Wells Fargo

$54.92

1.17 (2.18%)

17:08
10/20/17
10/20
17:08
10/20/17
17:08
Periodicals
Regulator criticizes Wells Fargo over deceptive auto insurance program, NYT says »

The Office of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

  • 07

    Nov

  • 29

    Nov

  • 15

    Jan

ALIM

Alimera Sciences

17:01
10/20/17
10/20
17:01
10/20/17
17:01
Syndicate
Alimera Sciences to sell $25M in shares in an 'at the market offering' »

On October 20, Alimera…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SYMC

Symantec

$32.66

0.33 (1.02%)

16:51
10/20/17
10/20
16:51
10/20/17
16:51
Syndicate
Breaking Syndicate news story on Symantec »

Symantec files to sell 1M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

EBMT

Eagle Bancorp

$19.55

0.15 (0.77%)

16:44
10/20/17
10/20
16:44
10/20/17
16:44
Hot Stocks
Breaking Hot Stocks news story on Eagle Bancorp »

EJF Capital reports 7%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$11.26

1.99 (21.47%)

16:43
10/20/17
10/20
16:43
10/20/17
16:43
Hot Stocks
Breaking Hot Stocks news story on KalVista »

Longwood Fund II reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JAGX

Jaguar Health

$0.19

0.002 (1.08%)

16:41
10/20/17
10/20
16:41
10/20/17
16:41
Syndicate
Breaking Syndicate news story on Jaguar Health »

Jaguar Health files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

$345.10

-6.71 (-1.91%)

16:40
10/20/17
10/20
16:40
10/20/17
16:40
Hot Stocks
Tesla amends 'warehouse agreements' to increase commitments to $1.1B »

On October 18,Tesla…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 06

    Nov

SNV

Synovus

$47.30

0.54 (1.15%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Hot Stocks
Synovus CBO sells 10,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Nov

  • 15

    Nov

GTXI

GTx

$7.92

0.1 (1.28%)

16:38
10/20/17
10/20
16:38
10/20/17
16:38
Syndicate
Breaking Syndicate news story on GTx »

GTx files to sell 8.77M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

, BKMU

BankMutual

$10.80

0.55 (5.37%)

16:36
10/20/17
10/20
16:36
10/20/17
16:36
Conference/Events
BankMutual to host special shareholder meeting »

Special Shareholder…

ASB

Associated Banc-Corp

$25.90

1.3 (5.28%)

BKMU

BankMutual

$10.80

0.55 (5.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

CNXR

Connecture

$0.49

-0.01 (-2.00%)

16:35
10/20/17
10/20
16:35
10/20/17
16:35
Hot Stocks
Breaking Hot Stocks news story on Connecture »

Connecture trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$23.83

0.25 (1.06%)

, PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

16:31
10/20/17
10/20
16:31
10/20/17
16:31
General news
On The Fly: Top stock stories for Friday »

Stocks opened sharply…

GE

General Electric

$23.83

0.25 (1.06%)

PG

Procter & Gamble

$88.25

-3.34 (-3.65%)

CELG

Celgene

$121.33

-14.63 (-10.76%)

SNCR

Synchronoss

$11.39

-0.12 (-1.04%)

IL

Bought by SNCR

SKX

Skechers

$33.99

9.96 (41.45%)

PYPL

PayPal

$70.97

3.72 (5.53%)

NCR

NCR Corp.

$33.05

-4 (-10.80%)

LHO

LaSalle Hotel

$28.52

-1.94 (-6.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 20

    Oct

  • 22

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 08

    Nov

  • 08

    Nov

  • 29

    Nov

  • 30

    Nov

16:30
10/20/17
10/20
16:30
10/20/17
16:30
Options
Preliminary option volume of 22.9M today »

Preliminary option volume…

MKL

Markel

$1,078.23

14.88 (1.40%)

, SNC

State National

$21.05

0.02 (0.10%)

16:26
10/20/17
10/20
16:26
10/20/17
16:26
Conference/Events
State National to host special shareholder meeting »

Special Shareholder…

MKL

Markel

$1,078.23

14.88 (1.40%)

SNC

State National

$21.05

0.02 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Oct

  • 26

    Oct

RYTM

Rhythm Pharmaceuticals

$23.08

-0.17 (-0.73%)

16:22
10/20/17
10/20
16:22
10/20/17
16:22
Hot Stocks
Breaking Hot Stocks news story on Rhythm Pharmaceuticals »

Orbimed Advisors reports…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.